Celldex Therapeutics annual return on equity
2022
2023
2024
2025
Celldex Therapeutics Return on Equity (ROE) Growth & History (CLDX)
Celldex Therapeutics's return on equity was −40.62% for fiscal 2025.
View full Celldex Therapeutics company overviewCelldex Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −40.62% | −13.77 pp |
| 2024 | 2024-12-31 | −26.84% | +10.60 pp |
| 2023 | 2023-12-31 | −37.45% | −7.32 pp |
| 2022 | 2022-12-31 | −30.13% | — |
Celldex Therapeutics quarterly return on equity
Q2.11
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −12.56% | −4.22 pp |
| Q1 2026 | 2026-03-31 | −16.00% | −8.58 pp |
| Q4 2025 | 2025-12-31 | −14.45% | −8.31 pp |
| Q3 2025 | 2025-09-30 | −10.69% | −5.43 pp |
| Q2 2025 | 2025-06-30 | −8.33% | −3.99 pp |
| Q1 2025 | 2025-03-31 | −7.42% | −2.24 pp |
| Q4 2024 | 2024-12-31 | −6.14% | — |
| Q3 2024 | 2024-09-30 | −5.27% | — |
| Q2 2024 | 2024-06-30 | −4.34% | — |
| Q1 2024 | 2024-03-31 | −5.18% | — |
| Q2 2011 | 2011-06-30 | −12.24% | — |
Celldex Therapeutics return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, Celldex Therapeutics's return on equity decreased from −30.13% to −40.62%, a change of −10.49 percentage points. The latest reported quarter, Q2 2026, shows −12.56%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Celldex Therapeutics source filings ↗